(NASDAQ: VOGX) Vogenx's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 71.03%.
Vogenx's earnings in 2026 is N/A.On average, 4 Wall Street analysts forecast VOGX's earnings for 2026 to be -$10,455,010, with the lowest VOGX earnings forecast at -$10,045,010, and the highest VOGX earnings forecast at -$10,762,511. On average, 3 Wall Street analysts forecast VOGX's earnings for 2027 to be -$25,001,111, with the lowest VOGX earnings forecast at -$24,020,676, and the highest VOGX earnings forecast at -$25,736,438.
In 2028, VOGX is forecast to generate -$59,245,058 in earnings, with the lowest earnings forecast at -$56,921,722 and the highest earnings forecast at -$60,987,560.